丹参酮ⅡA磺酸钠不同时点给药在高血压性脑出血治疗中的疗效及对神经保护作用

doi:10.3969/j.issn.1000-8535.2018.03.026

摘要/Abstract

摘要： 目的探讨高血压性脑出血在不同时点给药丹参酮ⅡA磺酸钠的疗效分析及对神经保护作用。方法选取我院2014年10月—2016年10月期间收治的66例高血压性脑出血患者作为研究对象,按照随机数字表的方法分为观察组(n=33)和对照组(n=33),对照组患者于入院后第10天采用丹参酮ⅡA磺酸钠进行治疗,观察组则于入院后第3天采用丹参酮ⅡA磺酸钠进行治疗,分别对2组患者的临床疗效、不良反应、治疗前后的神经功能以及随访一年的脑卒中影响量表(SIS)进行客观比较。结果经比较,观察组患者的临床总有效率为90.90%,对照组的临床总有效率为69.70%,2组比较,差异有统计学意义(P<0.05);观察组患者的不良反应稍低于对照组,但2组比较差异无统计学意义(P>0.05);此外,观察组患者治疗后的神经功能评分优于对照组和治疗前,差异有统计学意义(P<0.05);在随访一年的时间里发现,观察组患者的SIS量表亦更优于对照组(P<0.05)。结论早期采用药丹参酮ⅡA磺酸钠治疗高血压性脑出血的临床疗效显著,不良反应相对较小,且在一定程度上发挥了保护患者神经功能的作用,值得推广。

关键词: 高血压性脑出血, 不同时点, 丹参酮ⅡA磺酸钠, 临床疗效, 神经功能

Abstract: Objective: To investigate the effect of tanshinone II A sulfonate treatment on hypertensive cerebral hemorrhage at different time and the neuroprotective effect. Methods: In our hospital from October 2014 to October 2016 66 cases of hypertensive cerebral hemorrhage patients were enrolled as the research object, according to the random number table method divided into observation group (n=33) and control group (n=33), patients in the control group on the tenth day after admission of sodium tanshinone A sulfonate treatment, The observation group was treated with tanshinone A sodium sulfonate on the third day after admission. The clinical efficacy, adverse reactions, neurological function before and after treatment, and Stroke Scale (SIS) were compared between the two groups. Results: by comparison, the observation group of patients with clinical total efficiency 90.90%, clinical control group in the total efficiency 69.70%, compared with significant difference (P<0.05); to observe the adverse reaction of patients was slightly lower than that of control group, but the difference between the two groups was not statistically significant (P>0.05); in addition, the patients in the observation group the neurological score was significantly better than the control group and before treatment, the difference was significant (P<0.05); Conclusion: the early treatment of sodium tanshinone II A sulfonate in the treatment of hypertensive intracerebral hemorrhage has a significant clinical effect, a relatively small adverse reaction, and to a certain extent, it plays a protective role in patients with neurological function, and is worthy of promotion.

Key words: hypertensive intracerebral hemorrhage, different time points, sodium tanshinone II A sulfonate, clinical efficacy, neurologic function

肖媚, 李文礼, 罗伟汀. 丹参酮ⅡA磺酸钠不同时点给药在高血压性脑出血治疗中的疗效及对神经保护作用[J]. 广州医药, 2018, 49(3): 91-93.

XIAO Mei, LI Wenli, LUO Weiting. Clinical efficacy and neuroprotective effect of Tanshinone ⅡA sodium sulfonate in the treatment of hypertensive intracerebral hemorrhage[J]. Guangzhou Medical Journal, 2018, 49(3): 91-93.

参考文献

[1] 韩建立, 胡分彩. 高血压脑出血手术治疗时间的选择对患者疗效及生活质量的影响[J]. 现代中西医结合杂志, 2015, 24(1):85-86.
[2] 张毅, 方永军, 周锋,等. 丹参酮ⅡA磺酸钠注射液对脑出血大鼠灶周内源性神经干细胞的影响研究[J]. 实用心脑肺血管病杂志, 2015,23(10):45-49.
[3] YANG Q, ZHUANG X, PENG F, et al. Relationship of plasma matrix metalloproteinase-9 and hematoma expansion in acute hypertensive cerebral hemorrhage[J]. Int J Neurosci, 2016, 126(3):213.
[4] 张钶, 霍钢, 王晓澍,等. 早期强化降压对高血压脑出血患者颅内血肿及水肿的影响[J]. 第三军医大学学报, 2016, 38(7):757-760.
[5] 李延萍, 景蓉, 李水清,等. 早期肢体康复训练对高血压脑出血偏瘫患者神经功能恢复的影响[J]. 中西医结合心脑血管病杂志, 2015,13(6):844-846.
[6] 向飞, 邓民强, 汪逵. 高血压脑出血患者经丹参酮ⅡA治疗后血清白细胞介素-6及基质金属蛋白酶-9的动态变化[J]. 实用医学杂志, 2015, 31(1):131-134.
[7] 张毅, 方永军, 周锋,等. 丹参酮ⅡA对脑出血大鼠灶周Nestin、Neun表达的影响[J]. 陕西中医, 2015,36(11):1555-1558.
[8] 程艳, 封丽芳, 郑玉明,等. 丹参酮ⅡA磺酸钠治疗急性脑出血的安全性分析[J]. 中国医师进修杂志, 2014, 37(16):17-20.
[9] 孙奉辉, 徐依成, 陈新平,等. 高血压脑出血血肿周围水肿与动态血压的相关性研究[J]. 中华老年心脑血管病杂志, 2016, 18(6):571-573.
[10] 郑立冲, 王协锋. 微创颅内血肿清除术对高血压脑出血患者的疗效及炎性因子、血清铁蛋白、血清P物质的影响[J]. 解放军医药杂志, 2015, 27(10):59-63.
[11] 江思德, 邹耀兵, 唐明山,等. 高血压脑出血早期控制血压对血肿扩大的影响[J]. 重庆医学, 2015,44(23):3216-3217.
[12] 童民锋, 刘继红, 戴海斌. 醒脑静注射液对高血压脑出血患者临床指标的影响[J]. 中国临床药理学杂志, 2016, 32(5):399-401.
[13] 张洪涛, 禹萌, 任雅芳,等. 早期不同的血压控制目标对高血压性脑出血患者血肿扩大及预后的影响[J]. 南方医科大学学报, 2016, 36(12):1616-1620.
[14] MIYAGI T, KOGA M, YAMAGAMI H, et al. Reduced estimated glomerular filtration rate affects outcomes 3 months after intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study[J]. J Stroke Cerebrovasc Dis, 2015, 24(1):176-182.
[15] ADELI A, BEHROUZ R. The role of magnetic resonance imaging in management of patients with nonlobar hypertensive intracerebral hemorrhage[J]. Neurohospitalist, 2015, 5(2):59-62.